{"id":20108,"date":"2020-03-26T02:56:03","date_gmt":"2020-03-26T02:56:03","guid":{"rendered":"https:\/\/thepatientinvestor.com\/?p=20108"},"modified":"2020-03-26T03:02:04","modified_gmt":"2020-03-26T03:02:04","slug":"moderna-inc-mrna","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/","title":{"rendered":"Moderna Inc (MRNA)"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n\n
Stock:<\/td>\nModerna Inc<\/strong><\/td>\n<\/tr>\n
Exchange:<\/td>\nNasdaq<\/td>\nSymbol:<\/td>\nMRNA<\/strong><\/td>\n<\/tr>\n
Date:<\/td>\n25-Mar-20<\/td>\nLatest price:<\/td>\n$27.13<\/strong><\/td>\n<\/tr>\n
Market Cap:<\/td>\n$8.98 bn<\/td>\nFair Value:<\/td>\nUncertain<\/strong><\/td>\n<\/tr>\n
Forward P\/E:<\/td>\n\u00a0\u00a0\u00a0\u00a0\u00a0 –<\/td>\nPayback Period<\/td>\nUncertain<\/td>\n<\/tr>\n
Financial Y\/E:<\/td>\n31-Dec-20<\/td>\nRating:<\/td>\nBUY (above 30)
\n<\/strong><\/td>\n<\/tr>\n
Sector:<\/td>\nHealthcare<\/td>\nIndustry:<\/td>\nBiotechnology<\/td>\n<\/tr>\n
Investment Theme:<\/td>\nLT Growth<\/td>\nStructural Trends:<\/td>\nMedical Technology<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Moderna is at the forefront in developing a vaccine for the coronavirus COVID-19. Development work done on SARS and MERS vaccines has given the company a lead on competitors, with government approval to fast-track trial of the vaccine on humans.<\/p>\n

Summary<\/h2>\n

It is difficult to determine a fair value for Moderna \u2014 vaccines the company is working on are still in the development phase \u2014 but there is massive upside if development is successful. We rate MRNA as a BUY if it closes above 30.00.<\/p>\n

We suggest a weighting of 1% of portfolio value because of the uncertainty.<\/p>\n

Technical Analysis<\/h2>\n

Moderna (MRNA) was listed late 2018 and is testing resistance at its previous high of 30.00. Momentum is rising but declining Trend Index warns of strong resistance. A close above 30.00, or Trend Index recovering above zero, would be a buy signal.<\/p>\n

\"Twiggs<\/p>\n

Company Profile<\/h2>\n

Moderna is a clinical stage biotechnology company, based in Cambridge, Massachusetts, focused on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines.<\/p>\n

Messenger RNA plays a fundamental role in human biology, transferring the instructions stored in DNA to make the proteins required in every living cell. Moderna’s approach is to use mRNA medicines to instruct a patient\u2019s own cells to produce proteins that could prevent, treat, or cure disease.<\/p>\n

The firm uses mRNA to develop therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases.<\/p>\n

Coronavirus COVID-19<\/h3>\n

Moderna is at the forefront in developing a vaccine for the coronavirus COVID-19. Michael Diamond<\/a>, a viral immunologist at the Washington University School of Medicine in St. Louis, Missouri, and on Moderna\u2019s scientific advisory board, says the company has obtained FDA permission to commence phase 1 trials on human volunteers:<\/p>\n

A vaccine represents the best long-term defense against the virus, known as SARS-Cov-2, and could help thwart future outbreaks. But even if one is found to be safe and successful at preventing infection, public health experts say it will take at least a year to become widely available. While that seems like a long time, it\u2019s actually extremely fast for vaccine development.<\/p>\n

Just weeks after China shared the genetic sequence of the coronavirus in January, Moderna announced that it would ship its experimental vaccine to the U.S. government for testing. Last week, a handful of volunteers in Seattle became the first to receive that vaccine……<\/p>\n

A total of 45 healthy adults ages 18 to 55 years are expected to receive the investigational vaccine over the next six weeks. Known as a Phase I trial, this initial human study will test the safety of the vaccine as well as its ability to produce an immune response at three different doses. An effective vaccine must be able to create an immune response in the body that imitates an infection but doesn\u2019t make a person sick.<\/p>\n

Moderna manufactured the vaccine quickly, skipping lab experiments to determine how well it prevents infection in animals. Typically, scientists must test vaccines on animals before moving to human subjects, but the U.S. Food and Drug Administration has given Moderna permission to instead conduct animal tests in parallel with the human safety trial.<\/p>\n

Dr. Nathan Erdmann, an infectious disease physician at the University of Alabama at Birmingham, says the decision is warranted amid a public health crisis. \u201cFortunately, we had a head start on this…..Because of our experience with SARS and MERS, there\u2019s been work toward developing ways of having an immune response to a coronavirus vaccine for some time.\u201d<\/p>\n

….The viruses that cause SARS, or severe acute respiratory syndrome, and MERS, or Middle East respiratory syndrome, are also coronaviruses. Previous outbreaks of these diseases provided scientists with a starting point for making a coronavirus vaccine so quickly. Moderna was already working with researchers at the National Institute of Allergy and Infectious Diseases on an experimental MERS vaccine.<\/p>\n

Coronaviruses are sphere-shaped, with protein spikes protruding from their surface. These spikes lock onto human cells, allowing the virus to get inside and infect them. The vaccine that Moderna is developing consists of a short segment of genetic material, called messenger RNA, that provides instructions for a human cell to make a harmless version of the spike protein. The RNA is packaged into nanoparticles to be delivered as a vaccine. (Unlike some other vaccines, this one does not contain part of the actual pathogen.)<\/p>\n

Once in the body, the vaccine is meant to spur cells into producing some of the harmless spike proteins. If it succeeds, the immune system will recognize the spikes as foreign and unleash antibodies to attack them. These antibodies will continue to live in the body and would prevent infection if a person is exposed to the virus in the future.<\/p>\n

…..There is no vaccine on the market today that uses this approach. So far, this type of vaccine \u2014 known as an RNA vaccine \u2014 has only been tested on people in small safety trials. Scientists don\u2019t actually know how effective it is in people. In previous experiments on animals, RNA vaccines produced antibody levels \u201cin the same ballpark\u201d as other types of vaccines, says Diamond.<\/p>\n

RNA vaccines have some advantages compared to current vaccines. \u201cThey can be developed and deployed very rapidly,\u201d says Diamond, [who] worked with the company on an RNA vaccine for Zika virus. The process is much faster than other methods of making vaccines. Moderna was able to manufacture and ship the vaccine to the NIH for testing in a matter of weeks.<\/p>\n

\u201cEven generating the flu vaccine takes months and months, and we know exactly what we\u2019re working with year to year,\u201d says Erdmann.<\/p>\n

This type of vaccine could also be fairly inexpensive to manufacture because RNA is cheap to produce in the lab. Plus, some scientists think the risk for serious side effects is low because the body makes the protein itself. But because these vaccines haven\u2019t been tested widely in people, their side effects aren\u2019t well understood.<\/p><\/blockquote>\n

Even if Moderna does not win the race to produce a COVID-19 vaccine, the appeal of vaccines that do not contain part of the actual pathogen could go a long way towards overcoming anti-vaxxer<\/em> safety concerns surrounding vaccines.<\/p>\n

Financial Position<\/h2>\n

Moderna spends close to $500 million a year on research and development and has accumulated losses of $1.5 billion against contributed share capital of $2.7 billion.<\/p>\n

With cash balances of $1.1 billion and trade liabilities of $140 million, the company has roughly a two-year window to start generating revenue or else raise further capital.<\/p>\n

Disclosure<\/h4>\n

Staff of The Patient Investor may directly or indirectly own shares in the above company.<\/p>\n","protected":false},"excerpt":{"rendered":"

Stock: Moderna Inc Exchange: Nasdaq Symbol: MRNA Date: 25-Mar-20 Latest price: $27.13 Market Cap: $8.98 bn Fair Value: Uncertain Forward P\/E: \u00a0\u00a0\u00a0\u00a0\u00a0 – Payback Period Uncertain Financial Y\/E: 31-Dec-20 Rating: BUY (above 30) Sector: Healthcare Industry: Biotechnology Investment Theme: LT Growth Structural Trends: Medical Technology Moderna is at the forefront in developing a vaccine for … <\/p>\n

Continue reading “Moderna Inc (MRNA)”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3803],"tags":[4197,4215,4272,4273,4274],"class_list":["post-20108","post","type-post","status-publish","format-standard","hentry","category-international-growth","tag-coronavirus","tag-covid-19","tag-moderna-inc","tag-mrna","tag-sars"],"yoast_head":"\nModerna Inc (MRNA) - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna Inc (MRNA) - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Stock: Moderna Inc Exchange: Nasdaq Symbol: MRNA Date: 25-Mar-20 Latest price: $27.13 Market Cap: $8.98 bn Fair Value: Uncertain Forward P\/E: \u00a0\u00a0\u00a0\u00a0\u00a0 – Payback Period Uncertain Financial Y\/E: 31-Dec-20 Rating: BUY (above 30) Sector: Healthcare Industry: Biotechnology Investment Theme: LT Growth Structural Trends: Medical Technology Moderna is at the forefront in developing a vaccine for … Continue reading "Moderna Inc (MRNA)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:author\" content=\"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-26T02:56:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-03-26T03:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/static.incrediblecharts.com\/images\/2020\/2020-03-25-mrna.png\" \/>\n<meta name=\"author\" content=\"Colin Twiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Colin Twiggs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/\"},\"author\":{\"name\":\"Colin Twiggs\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\"},\"headline\":\"Moderna Inc (MRNA)\",\"datePublished\":\"2020-03-26T02:56:03+00:00\",\"dateModified\":\"2020-03-26T03:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/\"},\"wordCount\":1135,\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2020\\\/2020-03-25-mrna.png\",\"keywords\":[\"Coronavirus\",\"COVID-19\",\"Moderna Inc\",\"MRNA\",\"SARS\"],\"articleSection\":[\"International Growth\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/\",\"name\":\"Moderna Inc (MRNA) - the patient investor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2020\\\/2020-03-25-mrna.png\",\"datePublished\":\"2020-03-26T02:56:03+00:00\",\"dateModified\":\"2020-03-26T03:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2020\\\/2020-03-25-mrna.png\",\"contentUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2020\\\/2020-03-25-mrna.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2020\\\/03\\\/26\\\/moderna-inc-mrna\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/thepatientinvestor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna Inc (MRNA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thepatientinvestor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61572934660810\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\",\"name\":\"Colin Twiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"caption\":\"Colin Twiggs\"},\"description\":\"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He co-founded Incredible Charts and writes the popular Trading Diary and Patient Investor newsletters. Using a top-down approach, Colin identifies key macro trends in the global economy before evaluating selected opportunities using a combination of fundamental and technical analysis. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\\\/2009 and 2020 bear markets well ahead of actual events. He founded PVT Capital (AFSL No. 546090) in May 2023, which offers investment strategy and advice to wholesale clients.\",\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/people\\\/The-Patient-Investor\\\/61572934660810\\\/\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\",\"https:\\\/\\\/au.linkedin.com\\\/in\\\/colintwiggs\"],\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/author\\\/investor\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna Inc (MRNA) - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Moderna Inc (MRNA) - the patient investor","og_description":"Stock: Moderna Inc Exchange: Nasdaq Symbol: MRNA Date: 25-Mar-20 Latest price: $27.13 Market Cap: $8.98 bn Fair Value: Uncertain Forward P\/E: \u00a0\u00a0\u00a0\u00a0\u00a0 – Payback Period Uncertain Financial Y\/E: 31-Dec-20 Rating: BUY (above 30) Sector: Healthcare Industry: Biotechnology Investment Theme: LT Growth Structural Trends: Medical Technology Moderna is at the forefront in developing a vaccine for … Continue reading \"Moderna Inc (MRNA)\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_author":"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","article_published_time":"2020-03-26T02:56:03+00:00","article_modified_time":"2020-03-26T03:02:04+00:00","og_image":[{"url":"http:\/\/static.incrediblecharts.com\/images\/2020\/2020-03-25-mrna.png","type":"","width":"","height":""}],"author":"Colin Twiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Colin Twiggs","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/"},"author":{"name":"Colin Twiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454"},"headline":"Moderna Inc (MRNA)","datePublished":"2020-03-26T02:56:03+00:00","dateModified":"2020-03-26T03:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/"},"wordCount":1135,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-03-25-mrna.png","keywords":["Coronavirus","COVID-19","Moderna Inc","MRNA","SARS"],"articleSection":["International Growth"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/","name":"Moderna Inc (MRNA) - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/#primaryimage"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-03-25-mrna.png","datePublished":"2020-03-26T02:56:03+00:00","dateModified":"2020-03-26T03:02:04+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/#primaryimage","url":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-03-25-mrna.png","contentUrl":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-03-25-mrna.png"},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/03\/26\/moderna-inc-mrna\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Moderna Inc (MRNA)"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454","name":"Colin Twiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","caption":"Colin Twiggs"},"description":"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He co-founded Incredible Charts and writes the popular Trading Diary and Patient Investor newsletters. Using a top-down approach, Colin identifies key macro trends in the global economy before evaluating selected opportunities using a combination of fundamental and technical analysis. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\/2009 and 2020 bear markets well ahead of actual events. He founded PVT Capital (AFSL No. 546090) in May 2023, which offers investment strategy and advice to wholesale clients.","sameAs":["https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","https:\/\/www.instagram.com\/colin_thepatientinvestor","https:\/\/au.linkedin.com\/in\/colintwiggs"],"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/investor\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-5ek","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":20552,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/19\/moderna-inc-mrna-2\/","url_meta":{"origin":20108,"position":0},"title":"Moderna Inc. (MRNA) phase 1 successful","author":"Colin Twiggs","date":"May 19, 2020","format":false,"excerpt":"From The New York Times: The drug maker Moderna said on Monday that the first coronavirus vaccine to be tested in people appeared to be safe and able to stimulate an immune response against the virus. The findings, which helped give Wall Street its best day in about six weeks,\u2026","rel":"","context":"In "International Growth"","block_context":{"text":"International Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/international-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":20559,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/20\/moderna-inc-mrna-in-the-news-again\/","url_meta":{"origin":20108,"position":1},"title":"Moderna Inc (MRNA) in the news again","author":"Colin Twiggs","date":"May 20, 2020","format":false,"excerpt":"Release of this STAT report on Moderna (MRNA) phase 1 trial results caused buyers to curb their enthusiasm for the stock today. Experts were cautious in their response to the recent Moderna announcement, citing: Absence of a matching announcement from the NIAID (National Institute for Allergy and Infectious Diseases); Tests\u2026","rel":"","context":"In "International Growth"","block_context":{"text":"International Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/international-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":23325,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/12\/21\/moderna-gets-fda-authorization\/","url_meta":{"origin":20108,"position":2},"title":"Moderna gets FDA authorization","author":"Colin Twiggs","date":"December 21, 2020","format":false,"excerpt":"FDA Commissioner Stephen Hahn The Food and Drug Administration has authorized the COVID-19 vaccine developed by Moderna for use in the United States. The vaccine can now be given to adults 18 years of age and older in the US. It was 94 percent effective against symptomatic COVID-19 in clinical\u2026","rel":"","context":"In "International Growth"","block_context":{"text":"International Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/international-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":63521,"url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/01\/28\/is-gold-in-a-blowoff\/","url_meta":{"origin":20108,"position":3},"title":"Is Gold in a Blowoff?","author":"Colin Twiggs","date":"January 28, 2026","format":false,"excerpt":"Moderna (MRNA), an American biotechnology company focused on RNA therapeutics, primarily mRNA vaccines, climbed from $20 before the COVID-19 outbreak in 2020 to almost $500 in August 2023. In the final stages of the uptrend, it doubled from $250 to nearly $500 in less than a month, exhibiting the familiar\u2026","rel":"","context":"In "Gold & Precious Metals"","block_context":{"text":"Gold & Precious Metals","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/gold-commodities\/gold-precious-metals\/"},"img":{"alt_text":"Moderna in 2023","src":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-01-27-mrna.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-01-27-mrna.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-01-27-mrna.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":61539,"url":"https:\/\/thepatientinvestor.com\/index.php\/2025\/04\/23\/blow-off-or-buy-the-dip\/","url_meta":{"origin":20108,"position":4},"title":"Blow-off or buy the dip?","author":"Colin Twiggs","date":"April 23, 2025","format":false,"excerpt":"President Charles de Gaulle once equated being an ally of the United States to sharing a lifeboat with an elephant. The last month has been like sharing a lifeboat with an elephant on ketamine. Gold epitomizes recent volatility in financial markets. It spiked up to $3,500 per ounce on President\u2026","rel":"","context":"In "Gold & Precious Metals"","block_context":{"text":"Gold & Precious Metals","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/gold-commodities\/gold-precious-metals\/"},"img":{"alt_text":"Spot Gold","src":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2025\/2025-04-22-gold.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2025\/2025-04-22-gold.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2025\/2025-04-22-gold.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":20270,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/04\/15\/international-growth-performance-at-31-march-2020\/","url_meta":{"origin":20108,"position":5},"title":"International Growth: Performance at 31 March 2020","author":"Andy","date":"April 15, 2020","format":false,"excerpt":"International Growth portfolio performance since inception on 1 July 2018 is set out below. This period is too short to give a real indication as to how the portfolio will perform in the long-term: we expect to hold most growth stocks for 5 to 10 years. Annualized performance is calculated\u2026","rel":"","context":"In "International Growth Performance"","block_context":{"text":"International Growth Performance","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/international-growth-performance\/"},"img":{"alt_text":"International Growth in USD - Performance since Inception: Portfolio 15.12%, Benchmark -1.04% (1-Jul-18 to 31-Mar-20)","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2020\/04\/international-performance-usd-20200331.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/20108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=20108"}],"version-history":[{"count":4,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/20108\/revisions"}],"predecessor-version":[{"id":20113,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/20108\/revisions\/20113"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=20108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=20108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=20108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}